Literature DB >> 21746829

The use of opioids for dyspnea in advanced disease.

Romayne Gallagher1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21746829      PMCID： PMC3134725          DOI： 10.1503/cmaj110024

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  5 in total

1.  Opioid use and survival at the end of life: a survey of a hospice population.

Authors:  Russell K Portenoy; Una Sibirceva; Randall Smout; Susan Horn; Stephen Connor; Ronald H Blum; Carol Spence; Perry G Fine
Journal:  J Pain Symptom Manage       Date:  2006-12       Impact factor: 3.612

Review 2.  Pharmacogenetics of opioids.

Authors:  Andrew A Somogyi; Daniel T Barratt; Janet K Coller
Journal:  Clin Pharmacol Ther       Date:  2007-03       Impact factor: 6.875

Review 3.  Opioid metabolism.

Authors:  Howard S Smith
Journal:  Mayo Clin Proc       Date:  2009-07       Impact factor: 7.616

4.  Is there a higher risk of respiratory depression in opioid-naïve palliative care patients during symptomatic therapy of dyspnea with strong opioids?

Authors:  Katri Elina Clemens; Ines Quednau; Eberhard Klaschik
Journal:  J Palliat Med       Date:  2008-03       Impact factor: 2.947

5.  Use of oxygen and opioids in the palliation of dyspnoea in hypoxic and non-hypoxic palliative care patients: a prospective study.

Authors:  Katri Elina Clemens; Ines Quednau; Eberhard Klaschik
Journal:  Support Care Cancer       Date:  2008-08-22       Impact factor: 3.603
  5 in total
  2 in total

1.  Dynamic Rhythmogenic Network States Drive Differential Opioid Responses in the In Vitro Respiratory Network.

Authors:  Nicholas J Burgraff; Nicholas E Bush; Jan M Ramirez; Nathan A Baertsch
Journal:  J Neurosci       Date:  2021-10-25       Impact factor: 6.709

Review 2.  Ongoing clinical trials and treatment options for patients with systemic sclerosis-associated interstitial lung disease.

Authors:  Dinesh Khanna; Donald P Tashkin; Christopher P Denton; Martin W Lubell; Cristina Vazquez-Mateo; Stephen Wax
Journal:  Rheumatology (Oxford)       Date:  2019-04-01       Impact factor: 7.580
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.